The DOI matches its Crossref record.
Hyperthyroidism in Children Treated with Long Term Medical Therapy: Twenty-Five Percent Remission Every Two Years*
Abstract
We use an antithyroid drug for the treatment of hyperthyroidism due to Graves' disease in children and adolescents for as long as the patients are willing to comply and/or tolerate the drug. In more than 60 patients treated since 1961, the remission rate was 25% in the first 2 yr. This report looks at these same patients again, followed for an additional 5 yr. Survival analysis methods applied to the follow-up data on 63 children confirm our original statistical findings and suggest a continuing remission rate of 25% every 2.1 +/- 0.4 (+/- SE) yr regardless of the duration of previous therapy. The median time to remission was 4.3 +/- 1.5 yr, and 75% of patients are predicted to be in remission in 10.9 +/- 2.3 yr. Of 36 patients who went into remission, defined by their being euthyroid for 1 yr after cessation of therapy, 1 relapsed, and 2 developed spontaneous hypothyroidism; the remainder are euthyroid 1-11.7 yr after therapy was discontinued. Of 14 who switched from medical therapy, 2 of 7 treated surgically and 4 of 7 treated with 131I are hypothyroid. Only 1 patient had a significant adverse reaction to both methimazole and propylthiouracil. While medical therapy may have some direct effect on the autoimmune response in hyperthyroidism, its role in affecting the time to ultimate remission is unknown. These data, however, describe the course of children so treated and allow us to present therapeutic options initially or during treatment based on statistically derived probabilities of outcome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although two decades ago it was suggested that 25% of children with GD go into remission with every 2 years of continued treatment (341), other studies of larger cohorts of pediatric patients with GD treated with ATDs for extended periods have not revealed similar remission rates (333,339,342).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [341]
Citations
Cited by
Sorted by citations
Items 101–195 of 195
Gu, Y., Liang, X., Liu, M. R., Wu, D., Li, W., Cao, B., Li, Y., Su, C., Chen, J., & Gong, C. (2020) · Pediatric Investigation · doi:10.1002/ped4.12219 · Cited by 10
“In previous studies of children who were treated with antithyroid medication, 25% achieved remission within 2 years of starting treatment.(2,4)”
BackgroundTreatment of Graves’ disease in children: The Portuguese experience
Marques, O., Antunes, A., & Oliveira, M. J. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.11.014 · Cited by 11
“, who found 1 case with arthritis out of 63 patients.(16) One of the goals of this study was to identify one or more predictive factors for ATD treatment definitive response.”
BackgroundApproach to the Patient: Management and the Long-term Consequences of Graves' Disease in Children
Rivkees, S. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac573 · Cited by 11
The natural history and prognostic factors of Graves' disease in Korean children and adolescents
Song, S. M., Youn, J.-S., Ko, J. M., et al. (2010) · Korean Journal of Pediatrics · doi:10.3345/kjp.2010.53.4.585 · Cited by 10
Use of Antihistamines After Serious Allergic Reaction to Methimazole in Pediatric Graves’ Disease
Toderian, A. B., & Lawson, M. L. (2014) · Pediatrics · doi:10.1542/peds.2013-1857 · Cited by 10
Long‐term outcomes of anti‐thyroid drug treatment in childhood‐onset Graves' disease
Puttawong, D., Mahachoklertwattana, P., Numthavaj, P., Woratanarat, P., Pongratanakul, S., Koad, P., & Poomthavorn, P. (2022) · Clinical Endocrinology · doi:10.1111/cen.14869 · Cited by 9
“Longer treatment duration was associated with higher remission rates.(10,11,13,14) Leger et al.”
BackgroundResultGarcía, F. M., Cayuela, A., Hernández, N. G., Viñau, F. L., Cruz, M. Á. M., Brocca, M. A. M., González, E. N., López, A. P., Relimpio, F., Moreno, A. S., et al. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)70648-x · Cited by 9
Should radioiodine be the first-line treatment for paediatric Graves’ disease?
West, J. D., Cheetham, T. D., Dane, C., & Natarajan, A. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0176 · Cited by 9
Utilização do 131I no tratamento da doença de Basedow-Graves na infância e adolescência
Monte, O., Calliari, L. E., & Longui, C. A. (2004) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302004000100018 · Cited by 9
Cole, M. F., Hynes, A. M., Howel, D., Hall, L., Abinun, M., Allahabadia, A., Barrett, T. G., Boelaert, K., Drake, A. J., Dimitri, P., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024705 · Cited by 8
Pediatric hyperthyroidism and thyroid eye disease management
Li, J., Austin, J., Douglas, R. S., & Nallasamy, S. (2023) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2023.02.008 · Cited by 10
Factors Predicting Treatment Failure in Patients Treated with Iodine-131 for Graves′ disease
Manohar, K., Mittal, B. R., Bhoil, A., et al. (2013) · World Journal of Nuclear Medicine · doi:10.4103/1450-1147.136693 · Cited by 8
“[2] Though anti-thyroid drugs are the usual initial treatment of choice, durable complete remission is infrequently achieved with anti-thyroid drugs alone and relapse rates can be 50-90% in patients with nodular goiters.[3-6] Radio-iodine ablation and surgery aim at reducing functioning thyroid volume, thereby reducin…”
BackgroundEnfermedad de Graves-Basedow en el niño preescolar
Pérez, A. C., Alcol, E. C., López-Capapé, M., Alonso‐Blanco, C., & Castellanos, R. B. (2005) · Anales de Pediatría · doi:10.1157/13078491 · Cited by 7
Which antithyroid drug regimen in paediatric G raves' disease?
Schenk, D. J., Donaldson, M., & Cheetham, T. D. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04509.x · Cited by 7
Cinemre, H., Bilir, C., Gökosmanoğlu, F., et al. (2009) · Clinical and investigative medicine · doi:10.25011/cim.v32i3.6108 · Cited by 7
The Medical Management of Graves’ Disease
Ross, D. S. (1995) · Endocrine Practice · doi:10.4158/ep.1.3.193 · Cited by 7
Molecular basis of virulence Commentary
Mitchell, T. J., & Finn, A. (1998) · Archives of Disease in Childhood · doi:10.1136/adc.78.3.197 · Cited by 6
Orgiazzi, J. (2015) · Clinical Thyroidology · doi:10.1089/ct.2015;27.302-305 · Cited by 6
Surgical management of benign thyroid disease in children
Zobel, M. J., & Padilla, B. E. (2020) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2020.150922 · Cited by 6
Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
Rho, J. G., Kum, C. D., Seo, Y., Shim, Y. S., Lee, H. S., & Hwang, J. S. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2040286.143 · Cited by 6
Thyroid Disorders in Children and Adolescents
Rivkees, S. A. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-156-5_7 · Cited by 6
Remission rate and remission predictors of Graves disease in children and adolescents
Lee, S. H., Lee, S. Y., Chung, H. R., Kim, J. H., Kim, J. H., Lee, Y. A., Yang, S. W., & Shin, C. H. (2009) · Korean Journal of Pediatrics · doi:10.3345/kjp.2009.52.9.1021 · Cited by 6
Enfermedad de Graves: estado actual y revisión de 20 casos
Cabezas, Ó. R., Calvo, M. A. M., Román, J. P., & Oliver, J. A. (2004) · Anales de Pediatría · doi:10.1016/s1695-4033(04)78370-8 · Cited by 6
Hwang, S. M., Kim, M. S., & Lee, D. (2016) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2016.21.2.70 · Cited by 5
ENDOCRINE DISORDERS AND TUMORS
Bae, J.-O., & Skinner, M. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6127-4.00078-1 · Cited by 5
Graves’ disease: developments in first-line antithyroid drugs in the young
Lane, L. C., & Cheetham, T. D. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1735359 · Cited by 5
Treatment of Graves’ disease in children: The Portuguese experience
Marques, O., Antunes, A., & Oliveira, M. J. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.03.008 · Cited by 5
Childhood Graves’ Disease—Remission Rate and Risk Factorse
Karlsson, F. A., Tuvemo, T., & Åkerström, G. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.4.4734-5 · Cited by 5
Traitement des hyperthyroïdies
Wémeau, J.-L., Carnaille, B. M. L., & Marchandise, X. (2007) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(07)41941-2 · Cited by 5
Brown, R. S. (2009) · Wiley eBooks · doi:10.1002/9781444316728.ch12 · Cited by 5
Relapse of Graves' disease in Chinese children: a retrospective cohort study
Cui, Y., Chen, J., Guo, R., Yang, R., Chen, D., Gu, W., Bigambo, F. M., & Wang, X. (2023) · European Thyroid Journal · doi:10.1530/etj-23-0018 · Cited by 4
Brown, R. S. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-9 · Cited by 4
Long-term outcome of treatments for Graves disease in the children and adolescent population
Jawwad, M., Ahmed, S. A., Zaidi, S. M. M., Fatmi, S. A. A., Ashraf, M. H., Naeem, S., & Chola, M. S. (2023) · Endocrine · doi:10.1007/s12020-023-03371-1 · Cited by 4
Federal clinical recommendations on diagnostics and treatment of Graves' disease in the children
Bezlepkina, O. B. (2014) · Problems of Endocrinology · doi:10.14341/probl201460359-68 · Cited by 4
Gill, D. S., Greening, J. E., Howlett, T. A., Levy, M. J., & Shenoy, S. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0385 · Cited by 4
Management guidelines for hyperthyroidism
Franklyn, J. A. (1997) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(97)80783-5 · Cited by 4
Thyroxine suppression therapy in Graves' disease
Toft, A. D. (1997) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(97)80753-7 · Cited by 4
Kim, W.-K., Ahn, B.-H., & Han, H. (2012) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2012.17.1.33 · Cited by 3
Initial Treatment of Pediatric Graves' Disease with Methimazole: A Retrospective Follow-up Study
Matsushita, R., Nakagawa, Y., Nagata, E., Satake, E., Sano, S., Yamaguchi, R., Fujisawa, Y., Masui, A., Nakanishi, T., Endo, A., et al. (2010) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.19.101 · Cited by 3
Hyperthyroidism (Graves' disease)
Castiglia, P. T. (1997) · Journal of Pediatric Health Care · doi:10.1016/s0891-5245(97)90106-1 · Cited by 3
Tratamento do hipertireoidismo na infância e adolescência
Sandrini, R., Nesi-França, S., de Lacerda, L., et al. (2001) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302001000100006 · Cited by 3
Hyperthyreose im Kindes- und Jugendalter
Doeker, B. M., & Andler, W. (1998) · Monatsschrift Kinderheilkunde · doi:10.1007/s001120050309 · Cited by 3
Peters, C. J., & Schoenmakers, N. A. (2019) · Wiley eBooks · doi:10.1002/9781119152712.ch8 · Cited by 3
Zheng, X., Zhu, Y., Chen, M. G., Su, Y. C., & Wu, X. M. (2025) · BMC Surgery · doi:10.1186/s12893-025-03081-7 · Cited by 3
Okamura, K. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2079 · Cited by 3
Management of the Various Causes of Thyrotoxicosis
Ross, D. S. (1997) · Humana Press eBooks · doi:10.1007/978-1-4757-2594-0_10 · Cited by 2
Smyczńyska, J., Cyniak-Magierska, A., Stasiak, M., Karbownik‐Lewińska, M., & Lewiñski, A. (2014) · PubMed · Cited by 2
McDermott, M., & Ridgway, E. C. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-5 · Cited by 2
Krane, E. J., Rhodes, E. T., Claure, R. E., Rowe, E. V., & Wolfsdorf, J. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-42974-0.00027-6 · Cited by 2
Antithyroid Drug Therapy in Patients with Graves’ Disease
Laurberg, P., & Cooper, D. S. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_6 · Cited by 2
Hyperthyroidism in children: treatment outcomes and preferences in Eastern India
Sanyal, D., & Chatterjee, S. (2015) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.24.63 · Cited by 2
“also reported 25% remission rates with ATD in children, which increased by 25% for every additional 2 yrs of therapy (6).”
BackgroundWafa, A. M. A.-E., Wahba, H. A., El-Hadaad, H. A., Elhadidi, A., & Halim, H. (2018) · Egyptian Journal of Obesity Diabetes and Endocrinology · doi:10.4103/ejode.ejode_5_18 · Cited by 1
Predicting the Likelihood of Remission in Children With Graves' Disease: A Prospective,
Glaser, N. S., & Styne, D. M. (2012) · Cited by 1
Thyroid Disease in the Elderly
Cappola, A. R., Miller, M., & Gambert, S. R. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-11 · Cited by 1
The Use of 131Iodine in the Treatment of Graves’ Disease in Children
Rivkees, S. A., & Dinauer, C. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374135-6.00098-4 · Cited by 1
Difficultés de prise en charge de la maladie de Basedow chez l’enfant : à propos d’un cas
Elouarradi, N., Mghari, G. E., & Ansari, N. E. (2018) · Pan African Medical Journal · doi:10.11604/pamj.2018.30.183.15325 · Cited by 1
“Le diagnostic positif de cette maladie est souvent facile mais la prise en charge adéquate de cette maladie reste un sujet de controverse en endocrinologie pédiatrique et la durée optimale du traitement médical pour induire une rémission de la maladie, reste à définir [2,3].”
MethodHyperthyroidism Due to Graves’ Disease, Toxic Nodules and Toxic Multinodular Goiter
Burman, K. D. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-3 · Cited by 1
Venkateswarlu, J., Hanmayyagari, B., Nagender, J., et al. (2014) · Thyroid Research and Practice · doi:10.4103/0973-0354.147280 · Cited by 1
Medical Treatment of Graves' Disease
Chung, H.-K. (2019) · International Journal of Thyroidology · doi:10.11106/ijt.2019.12.2.79 · Cited by 1
Management of Graves’ Disease in Children
Rivkees, S. A. (2000) · Endocrine updates · doi:10.1007/978-1-4615-4407-4_13 · Cited by 1
Childhood Graves’ Disease—Remission Rate and Risk Factors—Authors’ Responsef
Glaser, N. S., & Styne, D. M. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.4.4734-6 · Cited by 1
Krane, E. J., Rhodes, E. T., Neely, E. K., Wolfsdorf, J. I., & Chi, C. I. (2009) · Elsevier eBooks · doi:10.1016/b978-141603134-5.50028-7 · Cited by 1
Dong, B. J. (1992) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-13175-4_71 · Cited by 1
Management of the Various Causes of Thyrotoxicosis
Ross, D. S. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-352-1_9 · Cited by 1
Rivkees, S. A. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_11
POVIS, J. E. S., OKUMA, J. C. S., CARREÑO, S. E. C., et al. (2012) · Revista Médica Herediana · doi:10.20453/rmh.v17i1.898
Erkrankungen der endokrinen Drüsen
Bierich, J. R., von Harnack, G.-A., & Blunck, W. (1974) · Springer eBooks · doi:10.1007/978-3-642-96171-7_6
HOME | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | HELP
Weinmann, E. E., & Salzman, E. W. (2004)
Kiyaev, A. V., & Sumin, M. N. (2009) · Clinical and experimental thyroidology · doi:10.14341/ket20095223-29
Taquicardia paroxística supraventricular en una preescolar con tirotoxicosis
Hernández-Herrera, R. J., & Forsbach-Sánchez, G. (2014)
Hernández-Herrera, R. J., & Forsbach-Sánchez, G. (2014)
Erkrankungen der endokrinen Drüsen inkl. Diabetes und Wachstumsstörungen
Hiort, O., Kapellen, T. M., Pfäffle, R. W., Raile, K., & Willgerodt, H. (2007) · Elsevier eBooks · doi:10.1016/b978-343723200-8.50021-4
Betreuung von Kindern und Jugendlichen mit M. Basedow in einem endokrinologischen Zentrum
Penger, T., Albrecht, A., Marx, M., Jüngert, J., Kuwert, T., & Dörr, H. G. (2019) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-019-0650-3
Chiang, Y.-T., Ting, W., Huang, C., Huang, S.-K., Chan, C.-I., Cheng, B.-W., Lin, C., Wu, Y., Hung, C.-M., Li, H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/618942
Cole, M., Hynes, A. M., Howel, D., Hall, L., Abinun, M., Allahabadia, A., Barrett, T., Boelaert, K., Drake, A. J., Dimitri, P., et al. (2019) · Yearbook of pediatric endocrinology · doi:10.1530/ey.16.3.13
Kaplan, M. M., & Meier, D. A. (2000) · Endocrine updates · doi:10.1007/978-1-4615-4407-4_10
Léger, J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4745-2.00011-0
Thyroid and Parathyroid Glands
Nasir, A. A., Ameh, E. A., & Ridout, A. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-41724-6_40
Taking all the sideroads of hyperthyroidism therapy: Pitfalls and possibilities
Miletić, M., Stojanovic, M. M., Nedeljković-Beleslin, B., Stojković, M., Ćirić, J., & Žarković, M. (2021) · Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma · doi:10.5937/medgla2180108m
REINWEIN, D., & Klett, M. (1997) · Springer eBooks · doi:10.1007/978-3-642-59043-6_4
Erkrankungen der endokrinen Drüsen
Ranke, M. B., Dörr, H. G., von Harnack, G.-A., et al. (1994) · Springer eBooks · doi:10.1007/978-3-662-22535-6_4
tsch, J. D., Rascher, W., & rr, H. G. D. (2003) · Pediatric Drugs · doi:10.2165/00148581-200305020-00003
Management of thyrotoxicosis in children and adolescence: a Turkish multi-center experience
Esen, İ., Bayramoğlu, E., Yıldız, M., Aydın, M., Özturan, E. K., Aycan, Z., Bolu, S., Önal, H., Kör, Y., Ökdemir, D., et al. (2018) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.0210
Erkrankungen der endokrinen Drüsen
Ranke, M. B., Dörr, H. G., von Harnack, G.-A., et al. (1991) · Springer eBooks · doi:10.1007/978-3-662-10465-1_4
Antithyroid drug treatment for thyrotoxicosis
Toft, A. D. (2011) · doi:10.1093/med/9780199235292.003.3189
Messazos, B., Mihai, R., & Ryan, F. J. (2017) · Springer eBooks · doi:10.1007/978-3-662-54256-9_2
“Treatment with antithyroid drugs should be for a minimum of 2 years as this has been shown to decrease the risk of relapse [9, 31].”
BackgroundCherella, C. E., & Smith, J. R. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_15
(2000) · Time to knit · doi:10.1016/s1155-1941(19)30263-x
10.1016/b978-0-323-54940-0.00075-4
(2000) · Time to knit · doi:10.1016/b978-0-323-54940-0.00075-4
Tuli, G., Munarin, J., Tessaris, D., Matarazzo, P., & SANCTIS, L. D. (2025) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06653-2
Кияев, А. В., & Sumin, M. (2009) · CyberLeninK (CyberLeninka)
Abbate, M. T. A., Vincenzi, G., Mora, S., Tarantola, G., Petralia, I. T., Santagiuliana, C., Del, G. L., Zanelli, S., & Vigone, M. C. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag130 · Cited by 3
Endocrine Disorders and Tumors
Santore, M. T., Clifton, M. S., & Alemayehu, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-12431-0.00072-3
Kopfschmerzen, Gewichtsverlust und arterielle Hypertonie
Paulun, A., Lösch, H. W., Ŝimić-Schleicher, G., et al. (2012) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-011-2601-5
Metadata
- Authors
- LIPPE, B. M., LANDAW, E. M., & KAPLAN, S. A.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1987-06
- Volume
- 64
- Issue
- 6
- Pages
- 1241-1245
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1992904825
- Cited by
- 192
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 8 · 2019: 15 · 2018: 9 · 2017: 5 · 2016: 3 · 2015: 7 · 2014: 12 · 2013: 3 · 2012: 7
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01am025744-06)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- pediatric hyperthyroidism, Graves' disease, antithyroid drug therapy, long-term medical therapy, remission rate, time to remission, hypothyroidism, relapse, methimazole, propylthiouracil, adverse drug reactions, survival analysis, treatment outcome prediction
- MeSH terms
- Child, Female, Graves Disease, Humans, Hyperthyroidism, Male, Methimazole, Propylthiouracil, Statistics as Topic, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
